Tezepelumab
- Generic Name
- Tezepelumab
- Brand Names
- Tezspire
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1572943-04-4
- Unique Ingredient Identifier
- RJ1IW3B4QX
- Background
Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling. Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes....
- Indication
Tezepelumab is indicated as an add-on maintenance treatment for patients aged 12 years and older with severe asthma. In Europe, it is reserved for patients who are inadequately controlled despite maintenance treatment with high-dose inhaled corticosteroids plus another drug.
...
- Associated Conditions
- Severe Asthma
- Associated Therapies
- -
Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma
- Conditions
- Interventions
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dr. Andrew Thamboo, MD
- Target Recruit Count
- 10
- Registration Number
- NCT06740045
Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 100
- Registration Number
- NCT06705764
- Locations
- 🇨🇦
Sturgeon Community Hospital, St. Albert, Alberta, Canada
🇨🇦University of Alberta, Edmonton, Ca-ab, Canada
Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres
- Conditions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06455462
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Tezepelumab Treatment in Korean Severe Asthma Patients
- Conditions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT06438913
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
- Conditions
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 66
- Registration Number
- NCT06230354
- Locations
- 🇬🇧
Royal Brompton Hospital - Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
🇬🇧Barts Health NHS Trust, London, United Kingdom
🇬🇧Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 372
- Registration Number
- NCT06023589
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 34
- Registration Number
- NCT05740748
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇨🇦University of Saskatchewan, Saskatoon, Saskatchewan, Canada
REVErsing Airway Remodelling With Tezepelumab
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 90
- Registration Number
- NCT05651841
- Locations
- 🇫🇷
CHRU Lille, Lille, France
🇫🇷APHP Bicêtre, le Kremlin-Bicêtre, France
🇫🇷Hôpital de la Croix Rousse, Lyon, France
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 360
- Registration Number
- NCT05583227
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 207
- Registration Number
- NCT05398263
- Locations
- 🇹🇷
Research Site, Yenimahalle, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.